Methods. We prospectively followed up 506 patients with cases of GBS who were admitted to our center from 1996 through 2006. We diagnosed 63 (12.4%) CMV-GBS cases by immunoglobulin (Ig) M detection and IgG avidity. Plasma CMV DNA was detected at hospital admission. Patient subgroups were compared using Fisher's exact test and the Wilcoxon rank-sum test. Temporal variations were analyzed with time series methods.
presence or absence of CMV DNA in the blood was not documented. Because of the small number of patients studied, epidemiological characteristics and specific prognostic features were not specified, and the risk of developing GBS following primary CMV infection was not determined. Furthermore, most of the studies were performed approximately 15 years ago, and there are no recent data concerning the epidemiology of CMV-GBS.
In this study, we report a series of 63 cases of CMV-GBS, which were identified from 1996 through 2006 in a French reference center for GBS. We report some new insights into the epidemiology and the prognostic features of CMV-GBS, as well as information concerning the relationship between CMV replication and GBS symptoms.
PATIENTS AND METHODS

Background Information
The intensive care unit (ICU) of the Raymond Poincaré hospital (Garches, France) is a regional reference center for the management of adult patients with GBS [8] [9] [10] [11] [12] [13] [14] . All patients who are admitted to the ICU with GBS are asked to participate in the current therapeutic protocols. Pretreatment serum samples are obtained at hospital admission and assayed for the presence of antibodies against C. jejuni, Mycoplasma pneumoniae, CMV, and Epstein-Barr virus [8, 13] . As previously described, patients are followed prospectively over a 12-month period [12] . Disability grade is assessed as described elsewhere [15] . Clinical data collection, serum antibody detection, and electrophysiological testing are part of the current treatment and management of patients with GBS who are admitted to our health care center. No ethical approval was required for this study; CMV DNA detection is performed routinely when antibodies to CMV are detected, and results do not have a bearing on the treatment and management decisions taken for patients.
Study Population
Five-hundred and six patients with clinically defined GBS [16] were admitted to our center from January 1996 through December 2006. Primary CMV infection was detected in 63 (12.5%) of the patients. Two patients also had evidence of recent infection by other possible triggering agents (C. jejuni and M. pneumoniae) and were excluded. We thus included 61 patients with GBS following primary CMV infection (CMV-GBS case patients).
CMV Serological Testing and Plasma CMV DNA Detection
We used the VIDAS CMV immunoglobulin (Ig) G and IgM kits with the mini-VIDAS multiparametric analyzer (bioMérieux). The specificity of IgM detection was confirmed by measuring IgG avidity with the Enzygnost anti-CMV/IgG test (Dade Behring), which was performed in 8 mol/L urea. Recent primary CMV infection was defined by the simultaneous detection of anti-CMV IgM and IgG presenting an avidity score ,35% [17, 18] . CMV DNA was detected in plasma by the use of in-house polymerase chain reaction assays [19, 20] .
Other Laboratory Methods
Aspartate and alanine aminotransferase levels were assayed in each patient; liver dysfunction was defined by liver enzyme elevation 1.5 times the upper limit of normal, as described in Sharshar et al [11] . IgM and IgG anti-gangliosides were detected by immunodot blot [21] and enzymatic immunoassay (GanglioCombi, Bühlmann Laboratories, Schönenbuch, Switzerland). A control group of 17 patients with primary CMV infection and no neurological symptoms were tested for the detection of anti-GM2 IgM.
Data from Epidemiological Networks
The prevalence of GBS was obtained from the French database ''Agence Technique de l'Information sur l'Hospitalisation'' (http://stats.atih.sante.fr/mco/catalogmco.php). The incidence of CMV primary infection was estimated from the count of French population (http://www.recensement.insee.fr/home. action) and the published CMV seroprevalence data [22, 23] . The incidence of C. jejuni enteritis in France was that estimated by the National Reference Center for Campylobacters and Helicobacters (http://lesrapports.ladocumentationfrancaise.fr/ BRP/074000285/0000.pdf).
Statistical Analyses
Characteristics of patient subgroups were compared using the Fisher's exact test and the Wilcoxon rank-sum test. A multivariable logistic regression model was used to account for confounding in the analysis of long-term sequelae. Seasonal trends for GBS cases were analyzed using the method of Jones et al [24] . Briefly, this is based on a Poisson model for monthly counts of cases with a potential linear trend in time and several harmonics for the seasonal pattern. The number of harmonics (seasonality periods) was determined using Akaike information criterion. All tests were 2-tailed, and statistical significance was set at P , .05. Statistical analyses were performed using R software, version 2.6.2 (The R Foundation for Statistical Computing).
RESULTS
Characteristics of Patients with CMV-GBS
The group of patients with CMV-GBS consisted of 28 male patients and 33 female patients, aged 18-66 years (median age, 32 years). Age distribution was different between the sexes. Among the male patients, 25 were 20-40 years of age. Among the female patients, 19 were 20-40 years of age, and 10 were .50 years of age.
Patients with CMV-GBS were significantly younger (P , .001) and were more likely to be female (P 5 .073), compared with patients with no sign of recent CMV infection (Table 1) . Preceding infectious events, such as isolated headache (P , .001) or fever (P 5 .03), were associated with CMV infection, and the number of days from infectious event to onset of GBS was higher in the CMV-GBS group (P 5 .01). Facial palsy was more frequent in the CMV-GBS group (P , 5 .001), and objective sensory defects tended to be more frequent (P 5 .053). Over 50% of CMV-GBS patients had elevated liver enzymes (vs 11.6% for other patients; P , .001). The detection of anti-GM2 IgM was more frequent among patients with CMV-GBS but was associated with CMV infection (P , .001), as indicated by positive anti-GM2 IgM in 9 (53%) of 17 control patients with primary CMV infection but no neurological symptoms. Electrophysiological tests, performed by the same NOTE. Data are no. (%) of cases, unless otherwise indicated. Three patients were not classified because of unknown cause (n 5 1), evidence of recent infection by both CMV and C. jejuni (n 5 1), or Mycoplasma pneumoniae (n 5 1). CMV, cytomegalovirus; GBS, Guillain-Barré syndrome; GI, gastrointestinal illness; ILS, influenza-like syndrome; Ig, immunoglobulin; IV, intravenous; Other, cases unrelated to primary CMV infection; PE, plasma exchange; RTI, respiratory tract infection.
a Comparison between CMV infection and others.
b Median age or number (range).
c Severe long-term disability was defined by a disability grade of 3 (able to walk 5 meters across an open space with assistance) to 4 (chair/bedbound, unable to walk as in grade 3); minor long-term disability was defined by a disability grade of 1 (minor symptoms and able to run) to 2 (able to walk 5 meters across an open space without assistance).
CMV-related GBS
experienced neurophysiologist (M.C.D.), indicated that 70% of patients with CMV-GBS had the primary demyelinating form of the disease, and only 7% had the primary axonal form (P 5 .016).
Plasma CMV DNA test results were positive in 62% (36 of 58) of the patients with CMV-GBS who were evaluated at admission to our center. Characteristics of patients with positive and patients with negative CMV DNA test results did not differ significantly. However, having positive CMV DNA test results tended to be associated with objective and deep sensory defects ( Table 2 ).
Outcome and Prognostic Factors
After hospital admission, 95% of patients with CMV-GBS received a specific treatment (vs 79.5% for other patients; P 5 .002), mostly plasma exchange (PE) (66% vs 42.3% for other patients; P 5 .002). Mechanical ventilation was required for 21 (34%) of patients with CMV-GBS, and 1 patient, a 42-year-old woman, died. Long-term prognosis was assessed after 1 year of follow-up of 57 patients with CMV-GBS. Thirteen patients (23%) had sequelae (either sensitive or motor sequelae). Of these patients, 7 had sequelae that corresponded to motor defects with a disability grade <2, and 2 had a facial palsy; 1 patient had objective sensory defects, and 4 had subjective sensory defects. Long-term sequelae were less severe in the CMV-GBS group (P 5 .008).
We analyzed the factors associated with the need for assisted ventilation (short-term prognostic factors) and 1-year sequelae (long-term prognostic factors) ( Table 3) . Short-term prognostic factors were shorter time-lag from GBS onset to hospital admission (P 5 .035), inability to walk (P , .001), bulbar dysfunction (P 5 .001), inability to lift head (P 5 .024), lower initial vital capacity (P 5 .017), and treatment with intravenous (IV) Ig (P 5 .002). Long-term prognostic factors were older age (P , .001), disability grade >4 at hospital admission (P 5 .01), and need for assisted ventilation (P 5 .005). Among the 13 patients who presented with long-term sequelae, 10 were .35 years old (vs 3 patients aged <35 years; P 5 .004) (Figure 1) . By multivariable analysis, age was found to be an independent predictor of severity grade at admission (adjusted odds ratio 1.83 per 10 years, [95% confidence interval, 1.05-3.19]; P 5 .032).
Temporal Variations
Monthly counts of cases and model predictions indicated that the annual number of CMV-GBS cases diminished from 1996 to 2006 (P 5 .019), whereas the total annual number of GBS cases remained stable during the same period (Figure 2 ). The percentage of CMV-GBS cases, relative to the total number of GBS cases, decreased from 23.4% in 1996 to 9.1% in 2006 (data not shown). CMV-GBS cases displayed an annual periodicity (P 5 .031), with 50% of the cases occurring from July through October and only 15% occurring from January through March.
Incidence of GBS following CMV and C. jejuni Infection
We estimated that there were 150,000 to 400,000 CMV primary infections per year, assuming that (i) CMV seroprevalence is 35.5%-45.8% among adults aged 18-60 and 20-66 years, respectively [22, 23] and that (ii) the French population for the corresponding age categories, in 2006, was 35-40 million. The mean number of GBS cases reported in France from 1997 through 2006 was 1900. In our study, the percentage of CMV -GBS cases in adults aged 18-60 and 20-66 years was 17.1% (57 CMV-GBS cases of 339 total cases) and 15.2% (58 CMV-GBS cases of 382 total cases), respectively. Thus, we estimated the total number of CMV-GBS cases to be 230-330 per year, and we estimated that the incidence of CMV-GBS, relative to the number of cases of primary CMV infection, was 0.6-2.2 per 1000. Likewise, assuming that, during 2004-2005, the annual number of cases of C. jejuni enteritis in France was 800,000-2,000,000 (http://lesrapports.ladocumentationfrancaise.fr/BRP/ 074000285/0000.pdf) and that 26.5% (134 of 506) of our GBS cases followed an infection due to C. jejuni, we estimated that the incidence of Cj-GBS, relative to the number of cases of C. jejuni enteritis, was 0.25-0.65 per 1000.
DISCUSSION
In this study, we confirmed that patients with CMV-GBS share common characteristics that distinguish them from patients with no sign of recent CMV infection [4, 6, 25, 26] . Patients with CMV-GBS are more likely to be young-,35 years old in most of the cases-and female. Clinically, they often present with sensory defects and facial palsy. Laboratory testing will frequently reveal increased liver enzyme levels, along with an anti-GM2 IgM response. The initial severity of GBS, estimated by the need for assisted ventilation, is similar to that presented in other patients. However, the long-term sequelae are milder than those in other patients. In our study, the CMV-GBS patients consisted of 2 subgroups, according to age. Most of the patients are included in the first subgroup, which comprises men and women 20-40 years of age, with a sex-ratio of 1.4. The second subgroup, which represents almost one-fifth of the patients, is almost exclusively female patients .50 years of age. To our knowledge, the latter subgroup has never been described, probably because of the small number of patients included in previous studies. These results reflect the epidemiology of primary CMV infection in France and other countries with high public health standards. Indeed, in these countries, CMV transmission normally takes place during infancy (either from mother-to-child or from child-to-child in nurseries and day-care centers), in young adults (by sexual relationships), or in grandmothers who acquire the infection from their grandchildren [27] [28] [29] .
Statistical analysis of our data indicates a steady reduction in the number of CMV-GBS cases from 1996 through 2006. Because there was no change in the inclusion procedure of patients with GBS, and because the total number of GBS cases remained constant during the studied period, this result is probably not related to a recruitment bias. On the other hand, it is consistent with the decreased prevalence of CMV infection among immunocompetent adults from European countries over the past 20 years, along with improved public health standards [30] .
The question of seasonal distribution of GBS has previously been discussed [2] . Epidemic forms of GBS, related to epidemics of C. jejuni enteritis, have been described in China [31] . In France, cases of GBS do not follow a seasonal pattern, as confirmed by our results (Figure 2 ). However, we have previously shown that the apparent absence of seasonal variation masked substantial seasonal differences when various etiological subgroups were studied independently. Indeed, we have observed that cases related to ''known agents'' (ie, C. jejuni and CMV) peaked during spring and summer and that cases related to ''unknown agents'' (most likely, influenza and other respiratory viruses [12] ) peaked during winter [13] . In the present study, we show that CMV-GBS cases follow an annual cycle, with most of the cases occurring from July through October. To date, no seasonal distribution of CMV infection has ever been demonstrated [30] , but the decrease of CMV incidence could reveal a seasonality that was previously undetected.
Although GBS may be triggered by various infectious agents, the risk of developing GBS after an infection appears to be specific to each agent. In the case of Cj-GBS, the incidence was estimated to be 1 case per 1000 C. jejuni infections in the United States [26] . On the other hand, we recently estimated the incidence of GBS related to influenza to be 4-7 cases per 100,000 cases of influenza [12] . To date, there are no available data concerning the risk of developing GBS following primary CMV infection. Our results show that the risk of developing GBS following primary CMV infection is close to 1 in 1000. We found that this risk is within the same range as the risk following C. jejuni enteritis (0.5 cases per 1000). This is far greater than the risk associated with influenza, which only becomes significant during seasons of ''major'' influenza epidemics (eg, 1996-1997 and 1999-2000 in France) [12] .
Factors predictive of the need for mechanical ventilation were similar to those identified in previous studies [8, 11] . They appear to be common to all etiological forms and are indicative of the intensity of attack on peripheral nerves, which is thought to be crucial for short-term outcome. Sharshar et al [11] has shown that, during the course of GBS (independent from etiology), the need for mechanical ventilation was associated with increased liver enzymes. Here, in the context of CMV infection, liver dysfunction was detected in 51% of the patients, and there were no significant differences between patients who required mechanical ventilation and patients who did not (Table 3) . Patients who required mechanical ventilation had more often been treated with IV Ig and had been treated less often with PE. This is related to the fact that, in GBS, PE is associated with a higher risk of pulmonary infection [15] . Thus, patients who require assisted ventilation are preferentially treated with IV Ig, whereas those who do not are more often treated with PE. However, our study was not designed to draw any conclusion over the possible impact of PE or IV Ig on the evolution of CMV-GBS.
We studied long-term sequelae after 1-year of follow-up in almost all of the patients, and thus our data could be used to specify prognostic factors. We found that long-term sequelae were less severe in patients with CMV-GBS than in other patients, as previously reported [4] . However, although no severe motor defect was observed (disability grade <2), nearly a quarter of the patients presented with disabling sequelae. We found that the grade of initial disability and age .35 years were significant prognostic factors (P , .001 and P 5 .004, respectively). The involvement of these factors in the long-term outcome of GBS has been previously reported [4, 32] , which is consistent with the hypothesis that long-term disability after GBS depends on both the intensity of the attack on peripheral nerves and on the quality of the recovery processes [8] .
To date, little is known about the physiopathology of CMV-GBS, and the roles of anti-ganglioside antibodies, cellular immune responses, and viral replication are not yet established. Our results confirm that the anti-GM2 IgM response is more closely associated with primary CMV infection than with GBS [25, 26, 33] . In contrast with Kaida et al [34] , they also show that serum anti-GM2 IgM are unlikely to significantly influence the pathogenesis of CMV-GBS [25] . The cellular immune response may therefore have a prominent role in the pathogenesis of CMV-GBS. This is supported by Hadden et al, who measured various cytokine receptors and adhesion molecules in the serum of 229 GBS patients. They reported that patients with CMV infection were more likely to have raised concentrations of molecules associated with T cell activation and migration than patients with C. jejuni infection or no infection [4] . Abnormally high percentages of CD8 lymphocytes have also been reported in two GBS cases with serological markers of previous CMV infection [35] .
The issue of the role of viral replication in the development of neurological defects has not yet been evaluated. In our study, almost two-thirds of patients with CMV-GBS had results positive for CMV DNA in their plasma at hospital admission (1-15 days after GBS onset), and this was unrelated to age or sex (results not shown). Viral replication, as assessed by detection of CMV DNA in the plasma, did not appear to be a significant predictive factor for short-term or long-term outcomes (Tables 2 and 3 ). This was consistent with the fact that viral replication was independent from the age, which in itself was a major prognostic factor. However, we observed an association between viral replication and sensory defects ( Table 2 ), suggesting that there could be a link-direct or indirect-between CMV replication and GBS. Additional studies are required to confirm these results, including accurate analysis of CMV DNA kinetics in blood during the course of the disease and a search for CMV DNA in cerebrospinal fluid. This last point is controversial: Steininger reported CMV DNA to be present in the cerebrospinal fluid of 31% of a group of 42 GBS patients with serological evidence of recent or past CMV infection. In contrast, Kuijf reported CMV DNA to be present in only 1 of 170 patients with GBS with similar characteristics [36, 37] . We were unable to address this question because most of the patients that we studied had a previous lumbar puncture prior to their admission to our center and were not resampled for ethical reasons.
The involvement of CMV replication in the onset and development of GBS is yet to be established. The central issue is whether early antiviral therapy will be of benefit during CMV-GBS, in addition to the usual treatment by PE or IV Ig. Ganciclovir has been reported to improve GBS symptoms in immunosuppressed patients with GBS associated with CMV in the context of solid-organ transplantation [38] . However, additional studies are required to confirm this effect.
